KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Assets (2017 - 2025)

Aquestive Therapeutics has reported Other Non-Current Assets over the past 9 years, most recently at $2.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.6 million for Q4 2025, down 37.44% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (down 37.44% YoY), and the annual figure for FY2025 was $2.6 million, down 37.44%.
  • Other Non-Current Assets for Q4 2025 was $2.6 million at Aquestive Therapeutics, down from $3.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for AQST hit a ceiling of $7.8 million in Q1 2021 and a floor of $2.6 million in Q4 2025.
  • Median Other Non-Current Assets over the past 5 years was $5.5 million (2023), compared with a mean of $5.4 million.
  • Biggest five-year swings in Other Non-Current Assets: soared 2620.49% in 2021 and later crashed 37.44% in 2025.
  • Aquestive Therapeutics' Other Non-Current Assets stood at $6.9 million in 2021, then decreased by 6.55% to $6.5 million in 2022, then dropped by 15.7% to $5.4 million in 2023, then decreased by 22.34% to $4.2 million in 2024, then crashed by 37.44% to $2.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.6 million (Q4 2025), $3.2 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.